TargetMol

Gallium maltolate

Product Code:
 
TAR-T27398
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27398-5mg5mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-1mL1 mL * 10 mM (in DMSO)£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-10mg10mg£131.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-25mg25mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-50mg50mg£225.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-100mg100mg£301.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-200mg200mg£417.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27398-500mg500mg£643.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Gallium maltolate is a ribonucleoside-diphosphate reductase inhibitor.
CAS:
108560-70-9
Formula:
C18H15GaO9
Molecular Weight:
445.032
Pathway:
DNA Damage/DNA Repair|Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
[Ga+3].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-]
Target:
DNA/RNA Synthesis

References

You R, et al. Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review. Can Respir J. 2018 Nov 18;2018:1015239. Picken C, et al. Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. J Clin Med. 2019 Apr 9;8(4). pii: E481. Verlinden NJ, et al. Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension. Ann Pharmacother. 2019 Apr 4:1060028019843665. Hopper RK, Rogers R, Lawrence KM, Hedrick HL. Reply. J Pediatr. 2019 Mar;206:305-306.